CKD Drug Pipeline Case Study For Biopharma Portfolio Strategy Growth

How a Global Biopharma Leader Re-Shaped Its CKD Strategy with Claight’s Pipeline Intelligence

A Strategic Case Study in Chronic Kidney Disease Drug Pipeline Analytics

Chronic kidney disease (CKD) now affects close to 800 million people globally and is projected to reach 1.6 billion cases by the early 2030s. This case study examines how Claight (Expert Market Research) delivered a comprehensive Chronic Kidney Disease Drug Pipeline Analysis Report that transformed a global biopharma client's approach to portfolio strategy, clinical development, and business development across the US and European markets.

The CKD Burden: Why This Opportunity Demands Urgent Strategic Clarity

Chronic kidney disease is no longer a peripheral concern in global health – it has become a defining challenge in cardiorenal and metabolic medicine. CKD currently affects an estimated 13% of the global adult population, and its trajectory is accelerating. The World Health Organization and leading nephrology bodies project that global CKD cases will rise from approximately 800 million today to 1.6 billion by the early 2030s, driven by ageing populations, rising rates of type 2 diabetes, and hypertension.

Mortality associated with CKD increased by 95% between 2000 and 2021, making it the ninth leading cause of death globally – ahead of several conditions that receive far greater research investment and public attention. In the United States, CKD affects roughly 37 million adults, with up to 90% of early-stage patients remaining undiagnosed due to the absence of symptoms in early disease. In Europe, the burden is equally significant, with Northern, Western, and Southern European health systems facing increasing pressure from dialysis demand, cardiovascular complications, and escalating care costs.

These epidemiological realities have created a large and urgent commercial opportunity. But the same forces attracting pharmaceutical investment into CKD have also produced a treatment landscape of extraordinary complexity, rapid evolution, and growing competitive density – particularly across the US and European markets that set global standards for regulatory approval, clinical evidence, and reimbursement.

Key Epidemiological Facts: CKD Global Burden 2025

• CKD is now the 9th leading cause of death globally
• ~800 million adults affected today; projected 1.6 billion by 2033
• 95% increase in CKD-related mortality from 2000 to 2021
• Up to 90% of early-stage CKD patients remain undiagnosed
• ~34% of US adults aged 65+ are affected by CKD
• ~1 in 3 adults with diabetes has CKD; ~1 in 5 with hypertension
• Only ~2% progress to end-stage renal disease (ESRD) – but that represents millions of patients
• Strong geographic burden in the US, EU, South Asia, and Southeast Asia

Read our Chronic Kidney Disease Epidemiology Forecast Report  for more details.

The Client: A Biopharma Leader at a CKD Strategic Crossroads

Our client – a multinational biopharmaceutical company with established capabilities in cardiovascular, metabolic, and renal medicine – was seeking to expand and sharpen its position in chronic kidney disease. While epidemiological projections indicated substantial long-term commercial opportunity, the organisation faced a set of converging strategic uncertainties that internal teams alone could not resolve.

The Core Challenge

Portfolio debates within the company were happening asset by asset, without a unified, quantitative view of the competitive pipeline. Leadership teams needed clarity on three linked questions:

• How crowded are different CKD segments by stage, indication, and mechanism of action – and where is the field already saturated with late-stage contenders?
• Where do genuine unmet needs and white spaces exist across CKD, cardiorenal, and metabolic phenotypes that could support sustainable differentiation?
• How should the organisation prioritise indications, modalities, and partnership targets for the next 5 to 10 years, given rapidly evolving pipelines in SGLT2 inhibitors, GLP-1/GIP agonists, HIF-PH inhibitors, cell therapies, and biologics?

These questions were particularly urgent in the context of the US and European markets, where regulators, payers, and clinicians are raising the bar for clinical evidence, demanding hard renal and cardiovascular outcomes, precision patient selection, and clearly differentiated benefit profiles. In short, the fundamental question was simple – but the stakes were high:

"Where should the next CKD bets be placed over the coming decade?"

Without a systematic, external, and data-driven view of the evolving CKD pipeline, the client risked making portfolio decisions based on incomplete internal assumptions, disconnected competitive snapshots, and historical precedent that no longer reflected the current competitive reality.

Our Approach: Pipeline Analytics as a Strategy Instrument

Claight was engaged to build a CKD pipeline intelligence view designed explicitly for strategy – not a generic landscape overview, not a catalogue of approved drugs, but a forward-looking map of emerging competition that could anchor portfolio, clinical, and partnership decisions across the US and European markets.

The Chronic Kidney Disease Drug Pipeline Analysis Report 2025 focused exclusively on assets in development – from preclinical through Phase IV – and was structured around three analytical pillars:

Data Sources and Quality Framework

All data were triangulated from authoritative, peer-reviewed, and institutionally validated sources, including:

• ClinicalTrials.gov, EU Clinical Trials Register and regional clinical trials registries for trial phase, enrollment, geography, and endpoints
• US FDA and European Medicines Agency (EMA) regulatory databases for development status and submission histories
• Company annual reports, investor presentations, and R&D pipeline disclosures
• Peer-reviewed publications and conference presentations from major nephrology congresses (ERA, ASN, ISN)
• Expert interviews with nephrologists, clinical pharmacologists, and industry thought leaders
• Industry databases and financial intelligence platforms

Strict, harmonised phase definitions were applied across all assets. A standardised classification of drug development stages – Preclinical, Phase I, Phase II, Phase III, and Phase IV – was used consistently throughout the analysis, enabling meaningful cross-sponsor and cross-mechanism comparisons.

Key Findings from the CKD Drug Pipeline Analysis

The Chronic Kidney Disease Drug Pipeline Analysis Report 2025 standardised and analysed 160+ pipeline assets across phases, mechanisms, routes of administration, indications, and sponsor types. Several quantitative patterns had direct strategic implications for the client:

Finding 1: A Mature, Crowded Mid- and Late-Stage Pipeline

One of the most significant findings was the concentration of pipeline activity at mid-to-late development stages. Phase II and Phase III candidates together account for nearly 70% of CKD pipeline assets, with a substantial Phase IV tail reflecting active post-marketing research. This confirmed that any new late-stage entrant would be competing against therapies already supported by extensive renal and cardiovascular outcomes data.

For the client, this reinforced a critical strategic truth: launching a broadly labelled "CKD" drug with marginal benefit differentiation would no longer be viable. Differentiation had to be much clearer, and target patient populations more tightly defined.

FIGURE 1: CKD Pipeline Assets by Clinical Development Phase (2025)

Source: Claight – CKD Drug Pipeline Analysis Report 2025 | Phase II + III = ~70% of total pipeline assets

Finding 2: Small-Molecule Oral Therapies Are the New Baseline

Small molecules dominate the CKD pipeline, accounting for 75 of the 160+ assets analysed. Biologics and peptides each represent approximately 11 products, with other modalities – iron-based compounds, nutraceuticals, polymer-based compounds, and monoclonal antibodies – present in smaller but growing numbers.

In parallel, oral delivery is the overwhelmingly dominant route of administration, with 89 oral products in development – far ahead of subcutaneous and intravenous options. This mirrors the success of SGLT2 inhibitors and the expanding role of oral GLP-1-based therapies in CKD management pathways.

FIGURE 2: CKD Pipeline by Molecule Type

Source: Claight – CKD Drug Pipeline Analysis Report 2025

FIGURE 3: CKD Pipeline by Route of Administration

Source: Claight – CKD Drug Pipeline Analysis Report 2025 | Oral therapies account for ~62% of pipeline assets

Strategic Insight: The Oral Small-Molecule Warning

For companies already strong in oral formulation and scale manufacturing, the dominance of oral small molecules was reassuring – but also a warning. Oral delivery and small-molecule format are now table stakes in CKD. Real competitive differentiation must come from mechanism of action, patient selection, trial endpoints, and demonstrated hard-outcome impact, not dosage form alone.

Finding 3: Mechanistic Hotspots and Under-Served Clinical Phenotypes

The report made mechanistic crowding and white spaces structurally visible. Development clusters strongly around broad CKD indications and CKD with diabetes, often within mixed cardiorenal populations – the most well-established and commercially validated patient segments.

Far fewer programmes target the more complex or less commercially certain phenotypes:

• CKD with hyperkalemia (potassium management remains undertreated)
• End-stage renal disease (ESRD) on dialysis – a high-burden, high-unmet-need population
• CKD with significant anaemia not responding to current ESA-based therapy
• High-proteinuria non-dialysis patients – a mechanistically distinct subgroup with high progression risk
• Autoimmune and inflammatory kidney disease (IgA nephropathy, lupus nephritis)
• Advanced anti-fibrotic approaches targeting structural kidney deterioration

Late-stage examples – including the ZENITH High Proteinuria trial (zibotentan plus dapagliflozin from AstraZeneca), patiromer RAAS-optimisation studies, and SGLT-based studies in advanced CKD – illustrated how leading companies were staking out both broad and niche competitive ground simultaneously.

Finding 4: Who Is Really Shaping the Global CKD Agenda

Sponsor-type analysis revealed a clear structural divide between how large pharmaceutical companies and academic/hospital centres approach the CKD pipeline:

• Large industry players drive the vast majority of Phase III and Phase IV innovation, with AstraZeneca, Novo Nordisk, Eli Lilly, Bayer, and Boehringer Ingelheim constructing integrated CKD and cardiorenal platforms spanning multiple mechanisms and indications.
• Academic centres and hospitals are more prominent in early-stage innovation, drug repurposing, and proof-of-concept studies – representing a rich source of emerging mechanisms for partnership or in-licensing.
• Biotech companies are filling important niches in cell therapy, biologics, and novel metabolic mechanisms, particularly in Phase I and early Phase II.

FIGURE 4: Key CKD Pipeline Companies and Their Strategic Focus (2025)

Source: Claight – CKD Drug Pipeline Analysis Report 2025 | Company profiling includes pipeline portfolio, trial activity, financials, and recent developments

For the client, this framing fundamentally recast the competitive landscape. Competitors were not merely advancing single assets – they were building CKD and cardiorenal platforms with the potential to command entire patient journeys, from early-stage disease management through to ESRD. Any partnership, licensing, or co-development decision would need to be selective and mechanism-driven, not opportunistic.

Strategic Impact: From Reactive Bets to a Coherent CKD Strategy

With the CKD Drug Pipeline Analysis Report 2025 as a shared reference, the client was able to move from reactive, asset-by-asset decisions to a coherent, evidence-grounded CKD strategy spanning North America, Europe, and other priority markets. The engagement produced four measurable strategic outcomes:

A Shift in How the Organisation Asks the Fundamental Question

Ultimately, the client moved away from asking "Can this asset find a place in CKD?" – a question that too often led to rationalising weak competitive positioning after the fact.

With the pipeline map in hand, the question became:

"In which clearly defined patient segments can we genuinely change the trajectory of kidney disease – and what internal and external moves will make that possible?"

This reframing – from reactive to prospective, from broad to precision-driven – is precisely what structured pipeline intelligence is designed to enable.

Why Pipeline Intelligence Matters in CKD – and Beyond

The CKD market is evolving from a broad therapeutic opportunity into a highly competitive, strategically segmented environment. The days of building a successful CKD franchise purely on the basis of participating in a large disease category are over.

Sustainable competitive advantage in CKD – and in cardiorenal medicine more broadly – now depends on answering a specific set of strategic questions before competitors do:

• Where is differentiation still possible across CKD indications, mechanisms, and patient phenotypes?
• Which mechanisms are becoming commoditised – and which are approaching pivotal inflection points before others have noticed?
• How are patient populations being redefined through precision medicine, combination therapy, and evolving regulatory expectations in the US and Europe?
• Who are the most credible partnership, licensing, or acquisition targets – and what are they likely to be worth at Phase III readout?

Pipeline intelligence therefore becomes more than a research exercise. It becomes a strategic capability – one that supports investment prioritisation, in-licensing decisions, clinical development planning, endpoint selection, and long-term commercial positioning across the US, European, and global nephrology markets.

For organisations operating in nephrology, cardiometabolic disease, or adjacent therapeutic areas, detailed pipeline analysis provides an early view of where the market is heading before competitive dynamics become fully visible through product launches alone. In CKD specifically, where development timelines from Phase II to launch can span 8 to 12 years, this early-warning visibility is commercially invaluable.

The Regulatory Dimension: FDA and EMA Expectations

In the US, the FDA has progressively raised expectations for CKD trials, prioritising hard composite renal endpoints (sustained eGFR decline, ESRD, or renal death) and cardiovascular outcomes over surrogate markers alone.

In Europe, the EMA similarly expects robust, long-term evidence of clinical benefit in defined patient populations, with increasing scrutiny on trial design, inclusion criteria, and the adequacy of background therapy.

Pipeline intelligence that incorporates regulatory trends – not just competitive activity – allows organisations to design development programmes that are regulatory-ready from the outset, reducing the risk of late-stage failure or narrowed label language.

How Claight Supports Strategic Healthcare Intelligence Globally

Claight (Expert Market Research) delivers customised healthcare market intelligence and strategic research solutions across pharmaceuticals, biotechnology, diagnostics, medical devices, and healthcare services. Our work combines deep secondary research, competitive intelligence, epidemiology analysis, and therapeutic landscape assessment to support evidence-based decision-making at the highest levels of pharmaceutical strategy.

We support global clients across North America, Europe, Asia-Pacific, and emerging markets – including pharmaceutical companies, biotechs, investors, regulatory organisations, healthcare associations, and policy institutions.

What Makes Our Approach Different

Our approach is designed not only to describe markets, but to help organisations anticipate strategic shifts, identify actionable opportunities, and build the shared evidence base needed for disciplined capital allocation and portfolio management.

• We combine quantitative pipeline analytics with qualitative expert intelligence – producing insights that are both data-grounded and commercially relevant.
• Our teams include sector-specialised analysts from top global universities, working as an extension of our clients' in-house strategy and intelligence functions.
• We take a forward-looking perspective: our pipeline analyses focus on where the market is heading, not just where it stands today.
• We understand the regulatory and market access environments in the US, Europe, and major growth markets – and integrate these dynamics into our strategic assessments.
• We are committed to authoritativeness: all data are sourced from peer-reviewed publications, official trial registries, regulatory databases, and established industry disclosures.

This Methodology Can Be Applied Across Therapeutic Areas

The CKD pipeline engagement described in this case study represents one example of how Claight applies structured pipeline analytics to support biopharma teams facing complex, crowded, and rapidly evolving therapeutic areas. The same framework can be adapted to:

• Cardiorenal and metabolic portfolios where multiple mechanisms converge on overlapping patient populations
• Oncology and immunology indications with rapid modality diversification and complex trial landscapes
• Rare diseases and precision medicine settings where early pipeline visibility is critical to licensing and partnership strategy
• Regional strategy questions – including where to conduct pivotal studies and how to navigate regulatory and access requirements across the US, Europe, Asia-Pacific, and emerging markets

Conclusion: Turning a Noisy Field Into a Clear Set of Strategic Options

Chronic kidney disease has moved to the centre of global pharmaceutical strategy – driven by its enormous and growing patient burden, its deep connections to diabetes, cardiovascular disease, and metabolic dysfunction, and the convergence of powerful new therapeutic mechanisms on overlapping patient populations.

But the very dynamism of the CKD pipeline that makes it commercially attractive also makes it strategically treacherous. Organisations that fail to maintain a systematic, current, and analytically rigorous view of the competitive landscape risk misallocating capital, missing emerging white spaces, and entering competitive battles they cannot win.

Through a structured, forward-looking pipeline intelligence approach, Claight helped a global biopharma client transform fragmented CKD market information into a coherent strategic framework for portfolio prioritisation, clinical development planning, and long-term investment decision-making – with specific attention to the US and European regulatory and competitive environments.

The result was not simply a better understanding of the CKD pipeline. It was a clearer view of where future competitive advantage could realistically be built – by patient segment, by mechanism, by geography, and by timing – in the US, European, and global nephrology markets.

Explore Custom Pharmaceutical Pipeline Intelligence

If you are evaluating your organisation's position in any therapeutic area, Claight can help you build the strategic pipeline view you need.

Contact us: [email protected]

Visit: www.expertmarketresearch.com

Our team is ready to support your next strategic intelligence engagement – across drug pipeline analysis, competitive intelligence, epidemiology assessment, market opportunity evaluation, and regulatory landscape review.